NCT07073170CompletedPhase 1
A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
A Phase 1, Participant- and Investigator-Blind, Placebo-Controlled, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Daily Doses of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 10 Jul 2025
- Start date
- 25 Jul 2025
- Primary completion date
- 27 Jan 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT07073170
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 36
- From 25 Jul 2025 to the primary completion date, 27 Jan 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have a significant history within the past 6 months or current evidence of comorbidities capable of altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
Other illness
- Have type 1 diabetes or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization
- Have had an episode of severe hypoglycemia within 6 months or have a history of hypoglycemia unawareness
- Have or have a history of pancreatitis
- Have signs and symptoms of liver disease, with the exception of non-alcoholic fatty liver disease
- Have a personal or family history of multiple endocrine neoplasia syndrome type 2 or medullary thyroid carcinoma
Other
- Have a clinically significant gastric emptying abnormality
- Have an uncontrolled endocrine abnormality
- Have an abnormal blood pressure or pulse rate
- Have a 12-lead electrocardiogram (ECG) abnormality
Who the study is looking for
- Are native Chinese
- Have type 2 diabetes for at least 6 months
- Have been treated with diet and exercise, with or without a stable dose of metformin for at least 3 months
- Have hemoglobin A1c (HbA1c) of at least 7% and no greater than 10%
- Have a body mass index (BMI) of at least 20 milligrams per square meter (kg/m2) and no greater than 40 kg/m2
- Have had a stable body weight for the 3 months prior to screening
- Women must not be of childbearing potential
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| West China Hospital of Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| Peking University First Hospital Coordinator of this site? Confirm its status | Dongcheng District | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.